M. Rizzo, I. Pezone, M. Amicone, E. Riccio, A. Pisani
{"title":"Mini Review: Heparin treatment in COVID-19: Where are we?","authors":"M. Rizzo, I. Pezone, M. Amicone, E. Riccio, A. Pisani","doi":"10.35841/2249-622X.72.19503","DOIUrl":null,"url":null,"abstract":"Coronavirus disease 2019 (COVID-19) is a severe acute respiratory syndrome with a high mortality rate; it is caused by SARS-CoV-2, a new virus of the Coronaviridae family that emerged in Wuhan, Hubei, China, in December 2019 and rapidly spread worldwide until declared by the World Health Organization a global pandemic on March 11th, 2020. The race for an effective drug to prevent or treat SARS-CoV-2 infection is the highest priority among health care providers, government officials, and the pharmaceutical industry. Despite scientific effort, no pharmacological intervention has proven definitively beneficial, and care is primarily supportive.","PeriodicalId":8517,"journal":{"name":"Asian Journal of Biomedical and Pharmaceutical Sciences","volume":"76 1","pages":"1-3"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Biomedical and Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35841/2249-622X.72.19503","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Coronavirus disease 2019 (COVID-19) is a severe acute respiratory syndrome with a high mortality rate; it is caused by SARS-CoV-2, a new virus of the Coronaviridae family that emerged in Wuhan, Hubei, China, in December 2019 and rapidly spread worldwide until declared by the World Health Organization a global pandemic on March 11th, 2020. The race for an effective drug to prevent or treat SARS-CoV-2 infection is the highest priority among health care providers, government officials, and the pharmaceutical industry. Despite scientific effort, no pharmacological intervention has proven definitively beneficial, and care is primarily supportive.